Introduction
gastric adenocarcinoma, breast cancer
GASTRIC ADENOCARCINOMA, BREAST CANCER
Nearly 70% of breast cancer is estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-).Much evidence supports a close interaction of the ER signaling with angiogenesis and its vascular endothelial growth factor receptor (VEGFR) signaling pathway.Apatinib, a small-molecule VEGFR-tyrosine kinase inhibitor, selectively acts on the intracellular ATP binding site of VEGFR-2, which plays a central role in the regulation of angiogenesis.At present,apatinib has been approved as third-line treatment for patients with advanced gastric adenocarcinoma in China, October 2014.